Aerie Pharmaceuticals, Inc. (AERI)
| Market Cap | 747.61M |
| Revenue (ttm) | 207.13M |
| Net Income (ttm) | -49.42M |
| Shares Out | 49.41M |
| EPS (ttm) | -1.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 654,480 |
| Open | 15.11 |
| Previous Close | 15.12 |
| Day's Range | 15.09 - 15.13 |
| 52-Week Range | 4.81 - 15.37 |
| Beta | -0.05 |
| Analysts | Buy |
| Price Target | 15.63 (+3.3%) |
| Earnings Date | Nov 2, 2022 |
About AERI
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle g... [Read more...]
Financial Performance
In 2021, AERI's revenue was $194.13 million, an increase of 133.51% compared to the previous year's $83.14 million. Losses were -$74.81 million, -59.14% less than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for AERI stock is "Buy." The 12-month stock price forecast is 15.63, which is an increase of 3.30% from the latest price.
News
Is Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year?
Here is how Aerie Pharmaceuticals (AERI) and Hanger (HNGR) have performed compared to their sector so far this year.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, ECOM, PFS, LBAI
NEW YORK , Sept. 28, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Vir...
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emergi...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, t...
Is Aerie Pharmaceuticals (AERI) Outperforming Other Medical Stocks This Year?
Here is how Aerie Pharmaceuticals (AERI) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Aerie (AERI) Rallies 205.6% in the Past Three Months: Here's Why
Aerie (AERI) shares have skyrocketed in the past three months after the company announced its definitive agreement with Alcon, wherein the latter will acquire the former for $770 million.
Has Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?
Here is how Aerie Pharmaceuticals (AERI) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Why Aerie Pharmaceuticals Was Soaring So High This Week
You'd vault skyward, too, if a big-pocketed company were willing to spend a lot of coin on acquiring you.
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ONEM, CCXI, AERI, SFT
NEW YORK , Aug. 25, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o...
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigat...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Aerie Pharmaceutic...
Don't Look for Alcon's Acquisition to Boost Share Price in Short Term
Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Aerie Pharmaceuticals, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - August 24, 2022) - Rigrodsky Law, P.A. is investigating Aerie Pharmaceuticals, Inc. ("Aerie") (NASDAQ: AERI) regarding possible breaches of fiduciary duties and o...
AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareh...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to Alcon for $15.25 per share is fair to Aerie s...
SHAREHOLDER ALERT: Weiss Law Investigates Aerie Pharmaceuticals, Inc.
NEW YORK , Aug. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or t...
Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up
Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.
Why Is Aerie Pharmaceuticals (AERI) Stock Up 35% Today?
Source: Shutterstock.com Aerie Pharmaceuticals (NASDAQ: AERI ) stock is rising higher on Tuesday following news of an acquisition deal with Alcon (NYSE: ALC ). Alcon is agreeing to acquire Aerie Pharmac...
Shareholder Alert: Ademi LLP investigates whether Aerie Pharmaceuticals, Inc. has obtained a Fair Price in its transa...
MILWAUKEE , Aug. 23, 2022 /PRNewswire/ -- Ademi LLP is investigating Aerie (NASDAQ: AERI) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon. Click here t...
Alcon to Acquire Aerie Pharmaceuticals for $15.25 a Share
Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
GENEVA & DURHAM, N.C.--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, ...
After Golden Cross, Aerie Pharmaceuticals (AERI)'s Technical Outlook is Bright
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Aerie Pharmaceuticals Announces New Employee Inducement Grant
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for...
Wall Street Analysts See a 75% Upside in Aerie (AERI): Can the Stock Really Move This High?
The consensus price target hints at a 75.1% upside potential for Aerie (AERI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revi...
Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat
Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of 38.46% and 2.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
DURHAM, N.C.DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic ...